

En Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LifeTech Scientific Corporation

先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT OF THE COMPANY

This announcement is made by LifeTech Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with information on the latest product development of the Company.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 3 November 2015, the first clinical trial of the Group’s FIM (first in man) aortic single branch stentgraft system (the “**Aortic Stentgraft System**”) was successfully completed on a patient in the People’s Republic of China (“**PRC**”). The said implantation was smooth and successful; the Aortic Stentgraft System implanted was accurately positioned. The related device used during the clinical trial was easy to operate. In addition, post-operative angiography showed that after the implantation of the Aortic Stentgraft System, the blood flow in all branch vessels of the aortic arch in the patient’s body was back to normal and the size of Aortic Stentgraft System was satisfactory and fit inside the patient’s body. The implantation of Aortic Stentgraft System has successfully saved the patient’s life.

Currently, Aortic Stentgraft System can be used for lesions near the opening of the left subclavian artery to maintain steady blood supply of the Aorta and left subclavian artery, thereby improving blood supply to a patient’s left limbs and neck area beside aorta. In addition, the research and development (“**R&D**”) of Aortic Stentgraft System is one of the most popular R&D area at the moment as Aortic Stentgraft System can be implanted in a patient’s carotid or anonyma to reconstruct the aortic arch to the largest possible extent.

The Board believes that the Group's Aortic Stentgraft System has a few distinctive features. For instance, the Aortic Stentgraft System is single-framed and can be used for lesions near the left subclavian artery; the size of Aortic Stentgraft System is designed according to the average aorta size of the population in the PRC such that it is likely a good match with a patient's vessels; the way the Aortic Stentgraft System is released after implantation allows accurate positioning and avoids subsequent moving out of position inside a patient's body; and the delivery system of the Aortic Stentgraft System is easy to operate thus saving the operation time.

By Order of the Board
LifeTech Scientific Corporation
XIE Yuehui
*Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 9 November 2015

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. WU Jianhui, Mr. MONAGHAN Shawn Del, Mr. JIANG Feng and Mr. CLEARY Christopher Michael being non-executive Directors; and Mr. LIANG Hsien Tse Joseph, Mr. ZHOU Gengshen and Mr. ZHOU Luming being independent non-executive Directors.